Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Trial of Darolutamide as a Prostate-Specific Membrane Antigen (PSMA) Expression Enhancer in Patients With Localized Prostate Cancer

NCT05900973 is registered in ClinicalTrials.gov with D'Or Institute for Research and Education as lead sponsor.

NCT NCT05900973
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05900973 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Trial of Darolutamide as a Prostate-Specific Membrane Antigen (PSMA) Expression Enhancer in Patients With Localized Prostate Cancer
Lead sponsor
D'Or Institute for Research and Education
Phase
Phase 2
Overall status
Unknown status
Start date
July 20, 2023
Completion date
May 24, 2025
Enrollment
19 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer